Literature DB >> 15681024

Overcoming limitations of natural anticancer drugs by combining with artificial agents.

Mikhail V Blagosklonny1.   

Abstract

During a billion years of evolution, living creatures have perfected cytotoxic agents to kill other organisms without killing themselves, thus providing us with antibiotics to kill bacteria without killing eukaryotic (e.g. human) cells. Some natural agents inhibit specifically most vital cellular structures and functions in cancer cells. However, nature was not creating antibiotics for cancer, and natural agents kill cancer cells precisely because they share targets with normal cells. To discriminate between particular cancer cells and normal cells, we can design or select artificial agents that are not necessarily lethal but are aimed either at cancer-specific targets or at dispensable and even unavailable (in cancer cells) targets. Using rational drug combinations, such selective agents can assist natural agents to eradicate cancer cells selectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681024     DOI: 10.1016/j.tips.2004.12.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  24 in total

1.  BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.

Authors:  Céline J Rocca; Daniele G Soares; Hana Bouzid; João A P Henriques; Annette K Larsen; Alexandre E Escargueil
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  Immunometabolism in biofilm infection: lessons from cancer.

Authors:  Rasoul Mirzaei; Niloofar Sabokroo; Yaghoub Ahmadyousefi; Hamid Motamedi; Sajad Karampoor
Journal:  Mol Med       Date:  2022-01-29       Impact factor: 6.354

3.  Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo[4,3-a]pyrimidinone Acyclo C-Nucleosides Multitarget Agents.

Authors:  Mohamed Nabil Abd Al Moaty; El Sayed Helmy El Ashry; Laila Fathy Awad; Nihal Ahmed Ibrahim; Marwa Muhammad Abu-Serie; Assem Barakat; Mezna Saleh Altowyan; Mohamed Teleb
Journal:  Molecules       Date:  2022-04-08       Impact factor: 4.927

4.  Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2012-06

5.  Hormesis does not make sense except in the light of TOR-driven aging.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2011-11       Impact factor: 5.682

6.  Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials.

Authors:  Miguel López-Lázaro
Journal:  Oncoscience       Date:  2015-02-20

Review 7.  Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems.

Authors:  Ivano Amelio; Vivien Landré; Richard A Knight; Andrey Lisitsa; Gerry Melino; Alexey V Antonov
Journal:  Oncotarget       Date:  2015

8.  Garlic (Allium sativum)-derived SEVs inhibit cancer cell proliferation and induce caspase mediated apoptosis.

Authors:  İrem Özkan; Polen Koçak; Merve Yıldırım; Naz Ünsal; Hazal Yılmaz; Dilek Telci; Fikrettin Şahin
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

9.  Metabolites from halophilic bacterial isolates Bacillus VITPS16 are cytotoxic against HeLa cells.

Authors:  Subramanian Prathiba; Varatharajan Sabareesh; Moorthy Anbalagan; Gurunathan Jayaraman
Journal:  3 Biotech       Date:  2021-05-18       Impact factor: 2.893

10.  Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays.

Authors:  Richard A Knight; Mikhail Gostev; Sergei Ilisavskii; Anne E Willis; Gerry Melino; Alexey V Antonov
Journal:  Oncotarget       Date:  2014-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.